Molecular mechanisms of AMPK mediated docetaxel-resistance in human prostate cancer
碩士 === 高雄醫學大學 === 醫學研究所碩士班 === 105 === Docetaxel is the first-line chemotherapeutic agent for patients with castration resistant prostate cancer (CRPC). Unfortunately, clinical treatment with docetaxel often encounters a number of undesirable side effects, including drug resistance. AMP-activated pr...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2017
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/69158788833945408088 |